Startseite Kongressberichte 2021 ESMO-Congress, Oct 07-11, 2016 - Copenhagen, Denmark More Highlights Metastatic Colorectal Cancer Sessions & Comments 1

PETACC8 Trial (2 Presentations)

P. Laurent-Puig1, R. Balogoun1, A. Cayre2, K. Le Malico, et al.:

ERBB2 alterations a new prognostic biomarker in stage III colon cancer from a FOLFOX based adjuvant trial (PETACC8)

Conclusions: ERBB2 alteration is a rare event found in approximately 4% of stage III CC pts. Its poor prognostic value supports the testing of anti-ERBB2 therapies in the adjuvant setting. 


 

J. Taieb, K. Le Malicot, R. Balogoum, J. Tabernero, et al.:

Adjuvant FOLFOX+ cetuximab vs FOLFOX in full RAS and BRAF wild type stage III colon cancer patients: Results from the PETACC8 trial.


Conclusions: In Stage III colon cancer, the addition of cetuximab to standard FOLFOX adjuvant therapy does not improve significantly outcome in RAS and RAS & BRAF double WT pts. No detrimental significant effect was observed in RAS mutant pts. NRAS or KRAS codon 61 seem to be the only rare mutations that has the same pejorative prognostic value than KRAS codon 12 and 13 or BRAF V600E mutations. 

Comment Julien Taieb, Department of Gastroenterology and GI oncology; Université Paris Descartes, Hopital European George Pompidou, Paris, France: